ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

PCSK9

proprotein convertase subtilisin/kexin type 9 · also NARC-1, FH3, HCHOLA3 · Proprotein convertase subtilisin/kexin family

12 programs in company-led studies act on PCSK9, from 11 companies: 6 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (11 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
inclisiranruleNovartisinhibitorphase 43715 running–the studies' text
evolocumabruleAmgen–phase 4452 running–NCIt
alirocumabruleSanofi–phase 4481 running–NCIt
lerodalcibepruleLIB Therapeuticsinhibitorphase 3147 running–ChEMBL
QLC7401ruleQilu Pharmaceuticallowers itphase 355 running–the studies' text
SYH2053ruleCSPC Pharmaceutical Grouplowers itphase 354 running–the studies' text
tafolecimabruleInnovent Biologics–phase 380 running–NCIt
recaticimabruleJiangsu HengRui Medicine–phase 370 running–the studies' text
SAL003ruleShenzhen Salubris Pharmaceuticals–phase 330 running–the studies' text
VERVE-102Eli Lilly–phase 222 running–a judged reading
DNV001ruleHangzhou Dinovate Biotech–phase 211 running–the studies' text
RBD7022ruleQilu Pharmaceuticallowers itphase 121 running–the studies' text

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.